Investigational drug · Phase 3
Aleniglipron
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Overweight, Chronic Weight Management.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
2 still active
All registered trials
8
Any phase or sponsor naming "Aleniglipron"
First trial start
2024
Oct 28, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Aleniglipron", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Overweight
- Chronic Weight Management
- Obesity, Overweight, or Chronic Weight Management
- Type2 Diabetes Mellitus
- Obese
- Obesity Type 2 Diabetes Mellitus
- Weight Loss
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Aleniglipron" as an intervention, largest first.
- Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)Pivotal-lookingRecruiting
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsIndustry
NCT07654361 · 3,600 participants (planned) · Start Jul 13, 2026 · Primary completion Sep 2028
Drug: Aleniglipron; Placebo · For: Obesity; Overweight; Chronic Weight Management
Sites: Birmingham, Alabama; Phoenix, Arizona; Sun City West, Arizona · 71 sites in all
- A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)Pivotal-lookingRecruiting
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsIndustry
NCT07654374 · 1,100 participants (planned) · Start Jul 17, 2026 · Primary completion Sep 2028
Drug: aleniglipron; aleniglipron and 2 more · For: Obesity; Overweight; Chronic Weight Management and 1 more
Sites: Birmingham, Alabama; Chandler, Arizona; Phoenix, Arizona · 74 sites in all
- A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityPivotal-lookingCompleted
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsIndustry
NCT06693843 · 230 participants · Start Oct 28, 2024 · Primary completion Oct 24, 2025
Drug: Aleniglipron or Placebo; Aleniglipron or Placebo and 5 more · For: Obesity, Overweight, or Chronic Weight Management
Sites: Phoenix, Arizona; Anaheim, California; Los Angeles, California · 39 sites in all
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsIndustry
NCT06703021 · 85 participants · Start Dec 20, 2024 · Primary completion Jan 12, 2026
Drug: aleniglipron or placebo; aleniglipron or placebo and 2 more · For: Obesity; Overweight; Chronic Weight Management
Sites: Glendale, California; Montclair, California; Valparaiso, Indiana · 10 sites in all
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsIndustry
NCT07169942 · 71 participants · Start Aug 15, 2025 · Primary completion Sep 9, 2026
Drug: aleniglipron or placebo · For: Obesity, Overweight, or Chronic Weight Management
Sites: Phoenix, Arizona; Chicago, Illinois; Richfield, Minnesota · 11 sites in all
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsIndustry
NCT07400588 · 58 participants · Start Dec 1, 2025 · Primary completion Sep 18, 2026
Drug: Aleniglipron; Placebo · For: Obese; Obesity; Obesity Type 2 Diabetes Mellitus and 1 more
Sites: Anniston, Alabama; Lake Forest, California; Lomita, California · 16 sites in all
- Aleniglipron Hepatic Impairment StudyRecruiting
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsIndustry
NCT07872033 · 36 participants (planned) · Start Oct 29, 2026 · Primary completion Aug 2027
Drug: Aleniglipron · For: Hepatic Impairment
Sites: Orlando, Florida; San Antonio, Texas
- Aleniglipron Renal Impairment StudyNot yet recruiting
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsIndustry
NCT07946068 · 16 participants (planned) · Start Dec 2026 · Primary completion Mar 2027
Drug: Aleniglipron · For: Renal Impairment; Severe Renal Impairment
Sites: Orlando, Florida
Newest research
PubMed records naming it or its code names, newest first.
- Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.
Rosenstock J, Lingvay I, Ryan D, et al. · Nat Med 2026
- Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.
Rosenstock J, Lingvay I, Ryan D, et al. · Nat Med 2026
- Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review.
Luna Ceron E, Reddy SD, Kattamuri L, et al. · J Brown Hosp Med 2025
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.